Products - Heart failure | Topic | NICE

Showing 28 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter

Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)
Product type:
Guidance
Programme:
HealthTech guidance
Published:
5 February 2026
Chronic heart failure in adults: diagnosis and management (NG106)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
3 September 2025
Published:
12 September 2018
Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (HTG730)
Product type:
Guidance
Programme:
HealthTech guidance
Published:
24 October 2024
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2023
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 June 2023
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) (TA790)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 May 2022
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 March 2022
Acute heart failure: diagnosis and management (CG187)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
17 November 2021
Published:
8 October 2014
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) (TA731)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 September 2021
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2016
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2014
Ivabradine for treating chronic heart failure (TA267)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 November 2012
Percutaneous insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
25 March 2026
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
25 March 2026
Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value Assessment
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
20 May 2026
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 June 2026
Implantable Vagus Nerve Stimulator in Heart Failure
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Rivaroxaban for treating chronic heart failure [ID1462]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
An aortic cuff counterpulsation system for the treatment of heart failure
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death
Status:
Awaiting development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [TSID12347]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC